Letter to the editor regarding "At Birth, Tales of Joy and Heartbreak"
By Marcy Darnovsky,
New York Times
| 10. 14. 2009
To the Editor:
“The Gift of Life, and Its Price” reports that the fertility industry’s professional organization encourages its members to transfer fewer embryos, so as to produce fewer multiple pregnancies and premature babies. The organization, the American Society for Reproductive Medicine, is to be commended for these efforts.
But its guidelines are routinely flouted. The society could put teeth behind its rules by publicly suspending the memberships of fertility practices in noncompliance. And it has resisted calls for public regulation and oversight.
Recent experiences with the financial sector have dramatized the dangers of inadequate public policy. The fertility industry, too, demonstrates the limits of self-regulation. Public regulation must be carefully written and not used to advance other agendas like opposition to reproductive rights. It’s past time for the federal government to set rules for the fertility industry and establish ways to enforce them.
Marcy Darnovsky
Berkeley, Calif., Oct. 11, 2009
The writer is associate executive director of the Center for Genetics and Society.
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...